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Henoch-Schönlein purpura (HSP) was first described by Heberden, in 1801, and its relationship with arthritis was highlighted by Schönlein, in 1837 [1]. HSP is 
a leukocytoclastic vasculitis with small vessel involvement; 
it mainly affects the skin as well as joints, the gastrointestinal 
system (GIS), kidneys, and, more rarely, other organs. Its etiology 
is not fully known [2] and it is the most widespread reason of 
non-thrombocytopenic purpura in children. It is a disease that is 
generally seen in children between the ages of 5 and 15 years. 
The estimated incidence of the disease in children <17 is 
13–20/100.000 [3].
Although the etiology of HSP is unknown, it has been reported 
that various factors such as infections, vaccines, drugs, foods, 
and insect bites trigger the disease [4]. The fact that two-thirds 
of the patients had a history of upper respiratory tract infection 
(URTI) and the disease was more commonly seen in winter and 
spring, when URTIs are very frequent, could be incidental, but 
it is more likely that HSP is linked to infectious diseases. The 
most important microorganisms are streptococci; in addition, 
many viral and other bacterial agents have also been reported to 
precipitating the disease [3]. IgA plays an important role in the 
pathogenesis of HSP. Studies have shown renal mesenchymal 
IgA accumulation, increased serum IgA, and the presence of IgA-
containing immune complexes in patients with HSP [5].
The most common and distinct sign of the disease is a skin 
rash in the form of non-thrombocytopenic palpable purpura that 
appears, especially on lower extremities. Non-thrombocytopenic 
purpura, arthritis, and abdominal pain in the early phase of 
the disease constitute the classic triad of symptoms of HSP 
and facilitate a clinical diagnosis [5]. The skin rash can be 
accompanied by soft tissue swelling, especially on the scalp, on 
the tibial aspect of the lower extremities, and on the back of the 
hands. Less frequently, localized edema on the eyelids, lips, ears, 
and perineum can be seen especially in younger children [6]. This 
edema is not associated with proteinuria, but it generally stems 
from angioedema and does not leave an indented mark when 
pressed [7]. Joint involvement in HSP manifests as arthralgia or 
arthritis. Knee, elbow, wrist, and ankle involvement are frequently 
seen. There is no intra-articular hemorrhage or effusion, nor 
permanent deformity [8].
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Background: Henoch-Schönlein purpura (HSP) is a leukocytoclastic vasculitis with small vessel involvement and mainly affects 
the skin as well as joints, the gastrointestinal system (GIS), kidneys, and, more rarely, other organs. Objective: The objective of this 
study was to evaluate the sociodemographic characteristics, and clinical and laboratory findings of patients diagnosed with HSP. 
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validated according to EULAR/PRINTO/PRES criteria. Mean standard deviation, median, lowest and highest, frequency, and ratio 
values were used in the descriptive statistics of the data. Results: The study included 85 patients between the ages of 2 and 16 years, 
wherein 49 patients (57.6%) were male and 36 (42.4%) were female. The mean age was 9.9±3.3 years and 53 patients (62.4%) were 
under 10 years of age. The most common precipitating factor was upper respiratory tract infections. Purpura was the only symptom 
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GIS involvement generally manifests as abdominal pain. 
If abdominal pain occurs before the rash, it can be confused 
with acute abdomen. Acute abdomen can be accompanied by 
vomiting and blood in stools [8,9]. In GIS involvement, serious 
life-threatening complications other than bleeding include 
intussusception and perforation. The diagnosis should always be 
considered in the case of very severe and long-term pain [8].
Long-term prognosis of HSP is determined by the severity 
of kidney involvement. The most common sign of kidney 
involvement is hematuria, which generally develops within 
the first 4 weeks. Proteinuria can be seen in various degrees of 
severity, ranging from mild proteinuria to severe proteinuria, as 
in nephrotic syndrome. Hypertension can generally be seen in the 
early stages. Kidney function tests are usually normal; however, 
some patients may develop severe kidney involvement and 
progressive glomerulonephritis [10].
Neurologic involvement is rarely seen in HSP. Central 
nervous system damage occurs either due to the direct effect of 
vasculitis or the indirect effect of systemic inflammation. Severe 
neurologic involvement is rare in HSP, whereas mild effects have 
been reported more frequently. In one study, 244 cases were 
retrospectively screened and it was found that 17 (6.9%) patients 
experienced convulsions and confusion. Recent studies have 
reported a much lower frequency of such symptoms [11].
HSP is the most common vasculitis of childhood and can cause 
serious complications. The aim of this study was to investigate 
the epidemiologic, clinical, and laboratory characteristics of 
patients with HSP who were admitted to our clinic and to review 
the treatment approaches for these patients.
MATERIALS AND METHODS
In this retrospective cross-sectional study, the sociodemographic 
data, clinical, laboratory findings, and treatment information of 
the patients hospitalized between January 1, 2008, and August 31, 
2013, with HSP in the pediatric clinic of a hospital, were recorded 
and evaluated.
HSP cases were validated according to EULAR/PRINTO/
PRES criteria [12]. Sociodemographic and epidemiologic 
characteristics (age, sex, and season), history (previous infections, 
insect bites, and trauma), complaints at admission, clinical 
progress, laboratory findings (full blood count, C-reactive protein 
[CRP], biochemistry, and complete urinalysis) of the patients, 
treatment approaches, and complications were retrospectively 
evaluated. Leukocyte count >13,000/mm3 was considered as 
leukocytosis; hemoglobin count <11 g/dl as anemia; platelet count 
>450,000/mm3 as thrombocytosis; and CRP >5 was considered to 
be high.
SPSS 22.0 software was used for the statistical analysis. Mean 
standard deviation, median, lowest and highest, frequency, and 
ratio values were used in the descriptive statistics of the data. 
Fisher’s exact test was used to analyze the qualitative independent 
variables. Statistical significance was construed as p<0.05.
RESULTS
A total of 85 patients with HSP were included in the study, of 
which, 49 patients (57.6%) were male and 36 (42.4%) were 
female, with male:female ratio of 1:36. The ages of the patients 
were between 2 and 16 years, and the mean age was 9.9±3.3 years. 
53 patients (62.4%) were under 10 and 32 patients (37.6%) were 
over 10. Considering the distribution of patients by the season 
of admission, 32 patients (37.6%) were presented in winter, 
22 (25.9%) in autumn, 19 (22.4%) in spring, and 12 (14.1%) 
in summer. Of the total study patients, 23 (27%) had a history 
of a potentially triggering factor before the onset of HSP. As 
a triggering factor, 20 patients (23.5%) had a history of URTI 
(rhinitis, otitis, tonsillitis, and pharyngitis) and three patients had 
a history of insect bites.
It was found that all patients had non-thrombocytopenic 
purpura ranging from petechiae to ecchymosis, and these lesions 
were localized most frequently on the lower extremities and hips, 
and less frequently on the upper extremities. Joint involvement 
was observed in 51 patients (60%). Joint involvement manifested 
as arthritis in 33 (38.8%) patients and arthralgia in 18 (21.2%) 
patients.
Gastrointestinal involvement was found in 50 patients (58.8%) 
and all these 50 patients had abdominal pain and 36 (42.3%) had 
gastrointestinal bleeding. The bleeding manifested as fecal occult 
blood in 33 patients (38.8%) and as gross bleeding in three patients. 
Abdominal ultrasonography (USG) revealed intussusceptions 
in one patient with severe abdominal pain. It was found that 
abdominal pain was an early symptom in 15 patients (17.6%) 
followed by purpuric rash. Renal involvement was detected in 
9 patients (10.6%). These patients had mild nephropathy along 
with microscopic hematuria. None of the patients had proteinuria 
or severe nephropathy.
The main laboratory findings in the acute phase of the disease 
were as follows: Mean leukocyte count was 11.5±3.4 (1000×/μl) 
and 26 patients (30.6%) had leukocytosis. The mean hemoglobin 
count was 13.3±1.1 g/dl and 10 patients (11.7%) were anemic. The 
mean platelet count was 364.2±117.9 (1000×/μl) and 19 patients 
(22.4%) had thrombocytosis. CRP was positive (>8 mg/dl) in 
40 patients (47%). The mean urea value was 24.3±8.5 mg/dL, 
and the mean creatinine value was 0.5±0.2 mg/dL. Creatinine 
values were within normal limits in all patients, whereas urea was 
higher than normal in four patients. The CRP-positive group had 
a significantly higher rate of arthritis as compared to the CRP-
negative group (p<0.05). There was no significant difference 
between CRP positivity and other clinical findings.
The rate of renal involvement with hematuria was significantly 
higher in the group with leukocytosis in comparison to the group 
without leukocytosis [Table 1].
It was observed that nonsteroidal anti-inflammatory drugs 
(ibuprofen, 30 mg/kg/day) were administered to 29 patients 
(34.1%), corticosteroids were administered to 38 patients (44.7%), 
and 18 patients (21.2%) were followed up without any treatment. 
Among the patients that received treatment, 44 (65.6%) had only GIS 
involvement, 2 (2.9%) had only renal involvement, and 7 (10.4%) 
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had both GIS and renal involvement. It was found that one patient 
developed intussusception as a complication and the other patients 
did not have any complications during the hospitalization period.
DISCUSSION
The findings of our study, i.e. age of the patients and the male-
to-female ratio (1.36:1) were similar to the data reported in other 
studies [13,14]. Although the disease is seen throughout the year, 
it is known that the disease is more frequent in winter as seen 
in our study; furthermore, it is followed by autumn. There are 
studies reporting that HSP is associated with respiratory tract 
infections, and the fact that the disease is more frequently seen 
in cold weather, especially in autumn and winter, implies that 
infections could be the triggering factor in the pathogenesis of 
this disease. However, this may be a coincidence on account of 
the increased incidence of URTI in children during winter [15].
Clinical findings from the patients revealed that all patients 
had a rash in the form of purpura. Lesions were localized generally 
on the lower extremities and rarely on the upper extremities 
and torso. Sometimes, skin findings are not present as the first 
symptom and can appear after arthritis or GIS symptoms. The 
occurrence of skin findings following joint and GIS involvement 
ranges between 25 and 50% [15,16]. Two different studies 
reported that joint involvement was seen in 15% and 25% of 
patients, respectively, and abdominal pain in 12% and 20% of 
patients, respectively, as initial symptoms [17,18]. Among our 
patients, 17.6% had abdominal pain and 18.8% had joint pain as 
initial symptoms and the results were similar to those in literature.
Arthritis is the second most common clinical presentation 
following rash in HSP patients. The rate of joint involvement 
ranges between 62 and 82%; the most common joint involvement 
was seen in the ankles and knees. Effusions are usually serous and 
not hemorrhagic and do not develop residual deformity or joint 
damage [15,16,19]. In our study, 60% of the patients had joint 
involvement. The most common joint involvement was seen in 
the ankles and knees, which is consistent with literature.
Studies reported a GIS participation rate of 38–75% in HSP. 
In one study, it was obtained that the rate of GIS involvement was 
62.3% and incident of fecal occult blood was 37.7% [3]. In our 
study, 58.8% of the patients had GIS involvement. All patients had 
abdominal pain, 38.8% of the patients had fecal occult blood and 
3.5% had fecal fresh red blood, all consistent with the data reported 
in literature. The most common surgical complication of HSP is 
intussusception. Radiologic, USG, and endoscopic assessment of 
patients presenting to the clinic with GI symptoms significantly 
reduced the number of unnecessary laparotomies. Studies that 
carried out gastrointestinal USG examinations in children with HSP, 
who also had abdominal pain, revealed increased duodenum wall 
thickness and echogenicity in 82%, increased duodenum diameter 
in 64%, and presence of gallbladder hydrops in 36% of these 
children. Some studies showed intestinal wall thickening, segmental 
dilatation of the intestine, and intestinal hypomotility in patients 
with HSP who were evaluated using abdominal USG [20,21].
In another study conducted by Connolly et al. [22], 
repeated USG of 12 patients with HSP showed decreased 
bowel wall thickening, a reduced amount of peritoneal fluid, 
return of peristalsis, and improved loose invaginations, and the 
improvement in sonographic findings were consistent with the 
clinical improvement. Therefore, it was reported that the severity 
and extent of gastrointestinal involvement could be monitored 
in HSP with repeat USG. In our study, an abdominal USG 
examination of a patient with abdominal pain showed requiring 
surgery.
The rate of renal involvement in HSP was reported to 
have a range between 10 and 60%, and the first signs of renal 
pathology are generally seen within 2 weeks after purpuric 
lesions are observed [23]. HSP nephritis generally manifests 
as mild proteinuria and/or microscopic hematuria that resolves 
spontaneously. However, renal involvement can be the primary 
cause of chronic kidney disease (CKD) in HSP. Therefore, kidney 
functions in HSP patients should be closely monitored, and 
treatment provided in the case of severe involvement [24]. A study 
by Sano et al. found that at the age of> 4 years, presence of severe 
gastrointestinal involvement, and purpura tending to last more 
than 1 month, was reported as risk factors for renal disease, and 
the most significant factor determining prognosis was reported 
the severity of renal symptoms at disease onset [25]. In our study, 
it was found that 10.6% of patients had renal involvement with 
microscopic hematuria, and renal symptoms appeared along with 
the rash or within the first few days. None of the patients had 
proteinuria and their blood pressure was within normal limits 
throughout hospitalization. In a study by Hamdan and Barqauri, 
the effect of age distribution on systemic involvement was 
investigated in 68 patients with HSP, and it was found that 19% 
Table 1: Relationship of the clinical findings to leukocytosis
Findings Yes/no Leukocytosis No leukocytosis
n (%) n (%) p
Abdominal 
pain
Yes 18 (69.20) 32 (54.20) 0.196
No 8 (30.80) 27 (45.80)
Arthritis Yes 11 (42.30) 22 (37.30) 0.602
No 15 (57.70) 37 (62.70)
Arthralgia Yes 4 (15.40) 14 (23.70) 0.386
No 22 (84.60) 45 (76.30)
Hematuria Yes 6 (23.10) 3 (5.10) 0.013*
No 20 (76.90) 56 (94.90)
Fecal occult 
blood
Yes 12 (46.20) 21 (35.60) 0.357
No 14 (53.80) 38 (64.40)
GIS 
hemorrhage
Yes 1 (3.80) 2 (3.40) 1.000
No 25 (96.20) 57 (96.60)
GIS 
involvement
Yes 17 (65.40) 33 (55.90) 0.415
No 9 (34.60) 26 (44.10)
Joint 
involvement
Yes 15 (57.70) 36 (61.00) 0.773
No 11 (42.30) 23 (39.00)
Renal 
involvement
Yes 6 (23.10) 3 (5.10) 0.013*
No 20 (76.90) 56 (94.90)
*p<0.05. GIS: Gastrointestinal system
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of the patients younger than 5 years and 67% of the patients older 
than 10 years had developed nephritis. Hence, it was highlighted 
that the development of nephritis was age dependent and the 
incidence of nephritis was higher in older children [26]. Similarly, 
our study has also demonstrated that 89% of the patients with renal 
involvement were older than 7 years. Consequently, urinalysis 
results and blood pressure should be monitored more carefully 
in the presence of renal involvement, especially in older children.
Laboratory tests are generally supplementary rather than 
diagnostic in HSP. In our study, the mean values of hemoglobin, 
leukocyte, platelet, urea, and creatinine parameters were within 
normal limits. Urea levels were higher than normal in four 
patients, but a relationship between elevated urea level and HSP 
could not be established in these patients as they did not have renal 
involvement. In all, 30.6% of the patients had leukocytosis, 22.4% 
had thrombocytosis, and 47% had CRP positivity. The detected 
high levels of acute phase reactants such as CRP, platelets, and 
leukocytes were consistent with other studies [19,27] and show that 
inflammation plays a role in the pathogenesis of HSP. The absence 
of other diseases and symptoms that may cause arthritis, URTI, 
or leukocytosis in patients with hematuria means that the risk of 
kidney involvement may increase in patients with leukocytosis. 
Even so, this field requires further prospective studies.
HSP is generally a self-limiting disease that does not require 
any special treatment other than support. Joint pain can usually 
be managed using analgesics such as ibuprofen. In patients with 
active GIS bleeding, nonsteroidal anti-inflammatory treatment 
for joint symptoms is undesirable. Hypertension is managed 
with suitable antihypertensive drugs. If there is an infection, it 
is treated with suitable antibiotics depending on the infectious 
agent and severity of infection. Surgery may be required for 
serious GIS complications. Severe skin symptoms, abdominal 
pain, and protein loss respond dramatically to oral corticosteroid 
treatment within a few days [16,27]. Corticosteroid treatment 
can lead to remission of arthritis and abdominal pain; however, 
it does not shorten the duration of the disease or prevent relapse. 
Starting steroid treatment in a patient with abdominal pain but 
no bleeding is considered undesirable as it may mask more 
severe complications. GIS symptoms exhibit remission without 
treatment in cases other than those requiring surgery. Starting 
treatment in the initial phase does not prevent the symptoms from 
developing. A few studies asserted that starting steroid treatment 
in the initial phase in patients (older than 7, with severe GIS 
involvement, and long-term purpura) who are suspected to have 
a high risk of developing kidney involvement could prevent renal 
damage [17,28].
Treatment protocols for Henoch-Schönlein nephritis are based 
on small series studies and a common consensus has not been 
reached on any of these protocols. Recent findings show that the 
combination of high-dose intravenous pulse methylprednisolone 
with azathioprine or cyclophosphamide could be beneficial in 
patients with severe nephritis [27]. There are also attempts to use 
plasmapheresis, Factor XIII concentrate, and urokinase in patients 
with severe nephritis. It is also reported that Dapsone treatment 
could contribute to the remission of HSP symptoms [17,28]. 
Recent studies showed that administering mycophenolate mofetil 
to patients who presented with nephrotic syndrome led to a 
significant remission in proteinuria after 1 month and full remission 
in 3 months, and slowed down the progression to CKD [29]. In 
our study, nonsteroidal anti-inflammatory drugs (ibuprofen, 
30 mg/kg/day) were administered to 34.1% of the patients, 
steroids (methylprednisolone 2 mg/kg/day) were administered to 
44.7% of the patients, and 21.2% of the patients were followed 
up without any treatment. It was found that joint symptoms in 
patients who only had joint involvement had clinically resolved 
without any residual damage after administration of nonsteroidal 
anti-inflammatory treatment for 1–2 weeks on average, during the 
hospitalization period. Steroid treatment was found to be needed 
in patients with severe gastrointestinal involvement (severe 
abdominal pain and GIS hemorrhage) and renal involvement for 
2–3 weeks on average. All patients who received steroid treatment 
due to severe GIS involvement exhibited clinical improvement 
in the acute phase, except for one patient. It was found that one 
patient with severe GIS symptoms developed intussusception as 
a complication and was operated on, whereas the other patients 
did not have any complications during the hospitalization period.
CONCLUSION
HSP is more commonly seen in children and leads to life-
threatening complications in a minority of patients. All patients 
with GIS symptoms should be examined using imaging methods 
and monitored to assess the severity of the disease, and any GIS 
complications should be observed and followed up. The risk of 
developing chronic glomerular disease is higher in older children 
(especially older than 7 years of age), patients who have more 
severe and long-term skin symptoms, leukocytosis, early renal 
findings, and serious abdominal symptoms. Therefore, these 
patients should be closely monitored.
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